PRECLINICAL STUDIES TO ASSESS ACUTE AND CHRONIC TOXICITIES OF A CANDIDATE DRUG BASED ON COMPLEMENT C3 NEODETERMINANT RECOMBINANT HUMANIZED ANTIBODY FOR TREATMENT OF TRAUMATIC BRAIN INJURIES
http://eng.biomos.ru/conference/articles.htmBIOTECHNOLOGY: STATE OF THE ART AND PERSPECTIVES(2021)
Abstract
A drug based on complement C3 neodeterminant recombinant humanized antibody for the treatment of traumatic brain injuries belongs to the class III of low-risk drugs.
MoreTranslated text
Key words
recombinant humanized antibody
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined